Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The investment will support Altay Therapeutics’ unique approach to finding an inhibitor of DUX4, a key transcription factor implicated in FSHD, that could provide an effective disease-modifying treatment.
Lead Product(s): Undisclosed
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: SOLVE FSHD
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 21, 2022